

PATENT

Case S0328

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Ish K. Khanna, et al.

SERIAL NO.:


09/882,186

FILED:

June 15, 2001

TITLE:

CYCLOALKYL ALKONOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS



GROUP ART UNIT:

EXAMINER:

DATE: June 17, 2002

TECH CENTER 1600/2900

JUN 26 2002

RECEIVED

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR 1.97-1.98

Commissioner of Patents and Trademarks

Washington, D.C. 20231

Sir:

This Supplemental Information Disclosure Statement is filed pursuant to 37 CFR 1.97-1.98 and MPEP §609. The present Information Disclosure Statement, supplements the Information Disclosure Statement being filed herewith simultaneously. Any fee required by 37 CFR 1.97-1.98 should be charged to Deposit Account No. 19-1025.

These newly cited documents are as pertinent as the documents previously cited in this prosecution.

Respectfully submitted,

Rachel A. Polster  
Registration No. 47,004  
(314) 694-7354 (St. Louis)

Pharmacia Corporation  
Corporate Patent Department  
800 North Lindbergh Boulevard  
St. Louis, Missouri 63167

**CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)**Applicant(s): **Ish K. Khanna, et al.**

Docket No.

**S03284**

Serial No.

**09/882,186**

Filing Date

**June 15, 2001**

Examiner

**TBA**

Group Art Unit

**TBA**Invention: **CYCLOALKYL ALKONOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS**I hereby certify that this **Supplemental Information Disclosure Statement**

(Identify type of correspondence)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to: The


Assistant Commissioner for Patents, Washington, D.C. 20231 on


**June 17, 2001**

(Date)

**Edwina Ragan**

(Typed or Printed Name of Person Mailing Correspondence)

  
(Signature of Person Mailing Correspondence)**Note: Each paper must have its own certificate of mailing.****RECEIVED**  
JUN 26 2002  
TECH CENTER 1600/2900



**FORM PTO-1449** U.S. DEPARTMENT OF  
COMMERCE, PATENT AND TRADEMARK OFFICE

ATTY. DOCKET  
NO.: S03284

APPLICATION NO.:  
09/882,186

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

INVENTOR: Ish K. Khanna et. al

Filed: June 15, 2001

Group:

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
A	5849736	12/15/1998	Wityak, et al.	514	227.8	05/31/1995
B	5665754	09/09/1997	Feldman, et al.	514	397	09/20/1993
C	5773644	06/30/1998	Chen, et al.	562	439	03/27/1997
D	5852210	12/22/1998	Chen, et al.	562	439	03/27/1997
E	5773646	06/30/1998	Chandrakumar, et al.	562	439	03/27/1997
F	3654306	04/04/1972	German, et al.	260	326.5	01/26/1970

**FOREIGN PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
G	WO 00/68195	16.11.2000	UK	C07D	207/16	X	
H	WO 00/33838	15.06.2000	US	A61K	31/435	X	
I	WO 94/27947	08.12.1994	UK	C07C	47/47	X	
J	EP 0747346	11.12.1996	US	C07C	233/18	X	
K	WO 97/19049	29.05.1997	Germany	C07C	229/48	X	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

Examiner Initial	
L	Wityak, et al., "Discovery of Orally Active Nonpeptide Vitronectin Receptor Antagonists Based on a 2-Benzazepine Gly-Asp Mimetic"; <i>Journal of Medicinal Chemistry</i> ; Vol. 43, No. 1, pp 22-26; January 2000
M	Miller, et al., "Discovery of Potent Isoxazoline Glycoprotein Hb/IIIa Receptor Antagonists"; <i>Journal of Medicinal Chemistry</i> ; Vol. 40, No. 1, pp 50-60; 1997

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

*Duplicate*

RECEIVED

TECH CENTER 1600/2500  
JUN 26 2002